COMPARISON OF EFFICACY OF COMBINATION OF METFORMIN PLUS MODIFIED-RELEASE GLICLAZIDE WITH COMBINATION OF METFORMIN PLUS SITAGLIPTIN IN PATIENTS WITH TYPE-2 DIABETES MELLITUS
DOI:
https://doi.org/10.47672/ajhmn.863Keywords:
Efficacy, Metformin plus modified-release Gliclazide, Metformin plus Sitagliptin, type-2 diabetes mellitus.Abstract
Introduction: Diabetes Mellitus (DM) is one of the leading causes of morbidity and mortality around the world and is responsible for 3.8 million deaths per year. Its prevalence had shown an exponential rise worldwide in the last two decades, from 30 million cases in 1985 to 177 million in 2000
Objective: To compare the efficacy of the combination of Metformin plus modified-release Gliclazide with a variety of Metformin plus Sitagliptin in patients with type-2 diabetes mellitus.
Methodology: This study was conducted at the Department of Medicine, Lady Reading Hospital Peshawar. The study design was a randomized controlled trial conducted for one year from May 2017 to May 2018, in which 62 patients in each group were observed. All patients with type 2 Diabetes Mellitus with baseline HbA1c ≥ 8% and duration >1 year, either gender with age range 35 to 65 years, were included. All patients were subjected to detailed history and clinical examinations. All patients were randomly allocated in two groups by lottery method. Patients in Group A were subjected to the combination of Metformin (1gm twice daily) with modified-release Gliclazide (60mg), and patients in Group B were subjected to the variety of Metformin (1 gm twice daily) with Sitagliptin (50 mg twice daily). All patients were followed up after three months, and blood samples for HbA1c levels were obtained. The analysis was done in SPSS version 20.
Results: The Study showed that the mean age in Group A was 58 years ± 12.78, and the mean age in Group B was 55 years ± 13.12. In Group A, 44% of patients were male, and 56% of patients were female, while in Group B, 45% of patients were male, and 55% of patients were female. Moreover, Group A (Metformin (1gm twice daily) + Gliclazide (60mg) was effective in 45% of patients while Group B Metformin (1 gm twice daily) + Sitagliptin (50 mg twice daily) was effective in 71% of patients.
Conclusion: Our study concludes that Metformin plus Sitagliptin is more effective than Metformin plus modified-release Gliclazide.
Downloads
References
The International Diabetes Federation. Diabetes epidemic out of control. 2006. http://www.idf.org/node/1354?unode=7F22F450-BIED-43BB-A57C-B975D16A812D
Power AC. Diabetes mellitus. In: Fauci AS, Kasper DL, Longo DL, Braunwald E, Hauser SL, Jameson JL, et al, editors. Harrison's principle of internal medicine. New York: The McGraw-Hill;2008.p.2276-92.
Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010 Jan;87(1):4-14.
Frier BM, Fisher M. Diabetes mellitus. In College NR, Walker BR, Ralston SH, editors. Davidson's Principles and Practice of Medicine. New Delhi: Elsevier;2010.p.798.
Maharani U. Diabetes Mellitus and Hypoglycemia. In: McPhee SJ, Papadakis MA, editors. Current Medical Diagnosis and Treatment. 51ST ed. New York: The McGraw-Hill Companies Inc; 2012.p. 1173-86.
Liu SC, Tu YK, Chien MN, Chien KL. Effect of antidiabetic agents added to Metformin on glycaemic control, hypoglycemia and weight change in a patient with type 2 diabetes: a network meta-analysis. Diabetes Obesity Metabolism. 2012:213-6.
Maharani U. Diabetes mellitus and hypoglycemia. In: McPhee SJ, Papadakis MA, editors. Current medical diagnosis and treatment. 51st ed. New York: The McGraw-Hill Companies Inc.; 2012. p. 1188-91.
Wu M, Meininger G. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New Eng J Med. 2008;358(24):2560-72.
Dodd AH, Colby MS, Boye KS, Fahlman C, Kim S, Briefel RR. Treatment approach and HbA1c control among US adults with type 2 diabetes: NHANES 1999-2004. Curr Med Res Opinion. 2009;25(7):1605-13.
Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with Metformin alone. Diabetes Care. 2006 Dec;29(12):2638-43.
Gale E, Anderson J. Diabetes Mellitus and other disorders of metabolism. In: Kumar P, Clark M, editors. Kumar and Clark's Clinical Medicine. Edinburgh: Elsevier Limited; 2009.p.1038.
Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care. 2004 Jan;27(1): 141-7.
Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with Sitagliptin, a dipeptidyl peptidase-4 inhibitor, and Metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007 Aug;30(8):1979-87.
Maharani U. Diabetes mellitus and hypoglycemia. In: McPhee SJ, Papadakis MA, editors. Current medical diagnosis and treatment. 50TH ed. New York: The McGraw-Hill Companies
Hou L, Zhao T, LIU Y, ZHANG Y. Efficacy and safety of Sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: A meta-analysis. Exp Ther Med. 2015;9(4):1528-36.
Mamza J, Mehta R, Donnelly R, Idris I. Comparative Efficacy of Adding Sitagliptin to Metformin, Sulfonylurea or Dual Therapy: A Propensity Score-Weighted Cohort Study. Diabetes Ther. 2015;6(2):213-26.
Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with Sitagliptin, a dipeptidyl peptidase-4 inhibitor, and Metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007 Aug;30(8):1979-87.
Maharani U. Diabetes mellitus and hypoglycemia. In: McPhee SJ, Papadakis MA, editors. Current medical diagnosis and treatment. 50TH ed. New York: The McGraw-Hill Companies
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Atta Muhammad Khan, Nowsherwan, Muhammad Abbass, Amjad Ali, Hussain Afridi, Wali Gul, Shah zaib
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
